Pharmion withdraws European thalidomide application
Pharmion withdraws its application for thalidomide in the treatment of multiple myeloma from the European Medicines Evaluation Agency, the company announces May 19. Pharmion said it will resubmit the application, which may allow for a broader label to include first line use. Pharmion partner Celgene has a thalidomide sNDA pending at FDA for use in multiple myeloma. Pharmion will evaluate whether Celgene's data is useful for European regulatory authorities...
You may also be interested in...
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.